Allergic Conjunctivitis
📧 Sign up to get email alerts when something new happens for Allergic Conjunctivitis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2009-09-23Clinical Trial Update: A Single-Center Evaluation of the Pattern of Allergic Signs and Symptoms During 4 Weeks in Ragweed Season
This completed single-center study evaluates the pattern of allergic signs and symptoms during a 4-week ragweed season in individuals with a…
-
FDA approval · 2009-09-08FDA Approved: BEPOTASTINE BESILATE — Original Application (Bausch & Lomb Americas Inc.)
FDA approved the original NDA for bepotastine besilate (Bausch & Lomb Americas Inc.), an ophthalmic antihistamine, for allergic conjunctivit…
-
CLINICAL_TRIALS trial_result · 2009-05-27Clinical Trial Update: Study of Two Marketed Ocular Anti-Allergy Medications in Subjects With Allergic Conjunctivitis [Phase 4]
Phase 4 trial update evaluating two marketed ocular anti-allergy medications in subjects with allergic conjunctivitis; results have been pos…
-
FDA approval · 2009-04-30FDA Approved: AZELASTINE HYDROCHLORIDE — Original Application (Apotex Corp.)
FDA approved Apotex Corp.'s original application for azelastine hydrochloride, a generic antihistamine product.
-
FDA approval · 2009-04-27FDA Approved: CETIRIZINE HYDROCHLORIDE ORAL SOLUTION — Original Application (APOZEAL PHARMACEUTICALS INC)
FDA approved Apozeal Pharmaceuticals' cetirizine hydrochloride oral solution as an original generic product.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2009-04-27Clinical Trial Update: Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis [Phase 2]
A Phase 2 trial of an immunomodulatory therapy for adults with perennial allergic rhinitis and rhinoconjunctivitis due to house dust mite an…
-
CLINICAL_TRIALS trial_result · 2009-04-09Clinical Trial Update: Evaluation of Efficacy and Safety of an Anti-Allergy Drug With a Contact Lens in the Treatment of Allergic Conjunctivitis [Phase 3]
A Phase 3 trial evaluated the efficacy and safety of an anti-allergy drug used with a contact lens for allergic conjunctivitis; the study ha…
-
CLINICAL_TRIALS trial_result · 2009-04-09Clinical Trial Update: Evaluation of Efficacy and Safety of an Anti-Allergy Drug With a Contact Lens in Allergic Conjunctivitis [Phase 3]
Phase 3 clinical trial evaluating the efficacy and safety of an anti-allergy drug delivered via a contact lens for allergic conjunctivitis c…
-
EMA withdrawal · 2008-11-18EMA Application withdrawn: Vekacia (ciclosporin) — Novagali Pharma S.A.
The EMA withdrew the application for Vekacia (ciclosporin) by Novagali Pharma S.A. for allergic conjunctivitis.
-
FDA approval · 2008-09-02FDA Approved: ZADITOR — Original Application (Alcon Laboratories, Inc.)
The FDA approved Alcon's ketotifen fumarate ophthalmic solution as a generic product under ANDA 077200 (brand name Zaditor).
-
FDA approval · 2008-07-07FDA Approved: ALOCRIL — Supplemental Application (Allergan, Inc.)
FDA approved a supplemental application for ALOCRIL (nedocromil sodium) from Allergan to update its labeling for allergic conjunctivitis.
-
CLINICAL_TRIALS trial_result · 2008-04-09Clinical Trial Update: A Comparison of Olopatadine and Fluticasone in Patients With Allergic Conjunctivitis [Phase 4]
Phase 4 clinical trial comparing olopatadine and fluticasone in allergic conjunctivitis has completed.
-
FDA approval · 2007-12-28FDA Approved: CETIRIZINE HCL — Original Application (GLENMARK THERAPEUTICS INC., USA)
FDA approved Glenmark's cetirizine HCl Original Application (ANDA), granting marketing rights for a generic cetirizine product. Indications …
-
CLINICAL_TRIALS trial_result · 2007-11-16Clinical Trial Update: Montelukast as a Controller of Atopic Syndrome [Phase 4]
Phase 4 clinical trial evaluating montelukast for control of atopic syndrome has completed, studying its effects in seasonal allergic rhinit…
-
FDA approval · 2007-10-18FDA Approved: XYZAL — Supplemental Application (Chattem, Inc.)
The FDA approved a supplemental application for XYZAL (levocetirizine dihydrochloride) submitted by Chattem, Inc.
-
FDA approval · 2007-08-21FDA Approved: ALOCRIL — Supplemental Application (Allergan, Inc.)
The FDA approved Allergan's supplemental application for ALOCRIL (nedocromil sodium) submitted by Allergan, Inc.
-
FDA approval · 2007-07-31FDA Approved: EYE ALLERGY RELIEF — Supplemental Application (DOLGENCORP, LLC)
FDA approved a supplemental application for Eye Allergy Relief containing pheniramine maleate and naphaZoline hydrochloride, manufactured by…
-
FDA approval · 2007-07-26FDA Approved: KETOTIFEN FUMARATE OPHTHALMIC SOLUTION — Original Application (Sentiss Pharmaceuticals LLC)
The FDA approved Ketotifen Fumarate Ophthalmic Solution as an original-application (ANDA) product from Sentiss Pharmaceuticals LLC for the t…
-
FDA label_change · 2007-06-08FDA Approved: PATADAY ONCE DAILY RELIEF — Supplemental Application (Alcon Laboratories, Inc.)
The FDA approved a supplemental application for PATADAY ONCE DAILY RELIEF (olopatadine hydrochloride) to support a once-daily dosing label f…
-
FDA approval · 2007-04-26FDA Approved: PATADAY ONCE DAILY RELIEF — Supplemental Application (Alcon Laboratories, Inc.)
FDA supplemental approval granted for Pataday Once Daily Relief with olopatadine hydrochloride, expanding labeling for once-daily dosing in …
-
FDA label_change · 2007-04-18FDA Approved: EYE ITCH RELIEF — Supplemental Application (Target Corporation)
FDA approves a supplemental application for Eye Itch Relief containing ketotifen fumarate, updating the product’s labeling.
-
CLINICAL_TRIALS trial_result · 2007-03-05Clinical Trial Update: Topical Tacrolimus 0.03% Ointment for Intractable Allergic Conjunctivitis: An Open Label Pilot Study [Phase 2]
Open-label Phase 2 pilot study evaluating topical tacrolimus 0.03% ointment for intractable allergic conjunctivitis.
-
FDA approval · 2006-12-01FDA Approved: EYE ITCH RELIEF — Original Application (Target Corporation)
FDA approved Eye Itch Relief from Target Corporation via an Original Application NDA for ketotifen fumarate eye drops, indicated for relief …
-
CLINICAL_TRIALS trial_result · 2006-11-07Clinical Trial Update: Alleviation of Cedar Pollen Induced Allergic Symptoms by Orally Taken Superfine Beta-1,3-Glucan [Phase 4]
A Phase 4 trial evaluated whether orally administered superfine beta-1,3-Glucan reduces cedar pollen–induced allergic symptoms, including al…
-
CLINICAL_TRIALS research · 2006-10-18Clinical Trial Update: Use of Probiotic Bacteria in Prevention of Allergic Disease in Children 1999-2008 [Phase 2, Phase 3]
Clinical trial update on using probiotic bacteria to prevent allergic diseases in children, spanning Phase 2 and Phase 3.